Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Pharm Res. 2019 Sep 16;36(11):161. doi: 10.1007/s11095-019-2691-7

Fig. 2.

Fig. 2

(a) Relative fluorescence of chitosan-pApoE2 complexes in different N/P ratios (1-5, 10, 15 and 20). Data are expressed as mean ± SD (n = 4). (b) Agarose gel electrophoresis of chitosan-pApoE2 complexes in different N/P ratios (1,5,10,15,20), lanes b-f, respectively). Naked pApoE2 (lane a) was used as control. (c) Protective effective of liposomal formulation containing chitosan-ApoE2 complexes (N/P 5) against nuclease degradation. Lane a, naked pApoE2; lane b, naked pApoE2 + DNase I; lanes c-f, Liposome, Tf-liposome, Pen-liposome, and Tf-Pen-liposomes containing chitosan-ApoE2 complexes, respectively + DNase I.